Here is IP Think Tank's weekly selection of top intellectual property news breaking in the blogosphere and internet.
Highlights this week included: copyright & trademark trolls, the constitutional challenge to Brazil's IP law, Norway & Croatia join the EPC, the EPO's financial crisis, France's new rules on liability of ISPs, Amazon's one click patent lives on (in amended form), and TiV's patent claims survive re-exam intact.
Please join the discussion by adding your comments on any of these stories, and please do let me know if you think we've missed something important, or if there is a source you think should be monitored.
You can separately subscribe to the IP Thinktank Global week in Review at http://duncanbucknell.com/subscribe/
Medicine 2.0: Online peer review? Facebook for physicians?: (MaRS),
Copyright and trade mark trolls?: (IPThinkTank),
ISPs fear trend towards greater liability for content: (IPWatch),
Customers lose faith in phished brands: (ArsTechnica)
Settling IP Litigation, Indian patent transparency, national differences, Friction & Warfighting: (StrategicIP),
Creative Commons is turning 5: (CreativeCommons),
Champerty in patent troll shell company cases: (Patent Prospector),
IP portfolio analysis: (IPThinkTank),
WIPO hosts international round table on the economics of IP: (WIPO)
When Yes is not enough: (IPThinkTank),
Bringing liquidity to the IP Marketplace: It's the information, stupid!: (Michael Pierantozzi),
ASEAN Regional patent office?: (IPThinkTank),
Convergence brings bad news for IP owners: (IAM),
DMCA-Style laws going to Canada, Switzerland and the world: (ArsTechnica),
Can typosquatting be counterfeiting?: (Trademark Blog),
Short paper on domain name monetization: (Trademark Blog),
Comcast puts non-lawyer in charge of IP Strategy: (IAM),
Are green technology IP rights owners about to become the new big pharma?: (IAM),
Latest WIPO SME newsletter: (WIPO),
Roche extends patent fight (to include Abbott) over diabetes test strips: (IPLaw360),
Drug innovation and marketing: (Tech Innovation and IP),
WHO funded study reveals 3.1% of drugs sold in India are counterfeit suspects: (SpicyIP),
Another piece on the impressive R&D programs of India's (generic?) pharmaceutical companies: (SpicyIP),
Great discussion on pharmaceuticals, patents and incentives for innovation: (Generic Pharmaceuticals & IP), (DrugWonks),
Adenoscan (Adenosine) - Astellas Pharma, King Pharmaceuticals, and Teva Settle Adenoscan Patent Suit: (PatentDocs),
Clarinex (Desloratadine) - Schering Corp. adds Anchen Pharmaceuticals Inc. to the long list of companies sued for patent infringement: (IPLaw360),
Cosopt (dorzolamide hydrochloride and timolol...